<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357617</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000490047</org_study_id>
    <secondary_id>CHUV-CEPO-161-05</secondary_id>
    <secondary_id>EU-20627</secondary_id>
    <nct_id>NCT00357617</nct_id>
  </id_info>
  <brief_title>Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery</brief_title>
  <official_title>Evaluation of the Effect of Celecoxib on Angiogenesis Markers in Patients With Operable Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Giving celecoxib before&#xD;
      surgery may reduce the amount of normal tissue that needs to be removed. Collecting and&#xD;
      storing samples of tumor tissue, blood, and urine from patients with head and neck cancer to&#xD;
      study in the laboratory may help doctors learn more about the cancer and predict how well&#xD;
      patients will respond to treatment with celecoxib.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying changes in tumor cells and how well celecoxib&#xD;
      works in treating patients with head and neck cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the changes in molecular markers of angiogenesis before and after treatment&#xD;
           with celecoxib in tumor tissues of patients with resectable head and neck squamous cell&#xD;
           carcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the changes in molecular markers of angiogenesis before and after treatment&#xD;
           with celecoxib in blood tissues of these patients.&#xD;
&#xD;
        -  Evaluate the effects of celecoxib on indirect measures of tumor perfusion, as measured&#xD;
           by perfusion CT scan, in these patients.&#xD;
&#xD;
        -  Evaluate the effects of celecoxib on apoptosis and proliferation rate on tumor cells and&#xD;
           on endothelial cells in these patients.&#xD;
&#xD;
        -  Identify potential new markers of the activity of cyclooxygenase-2 inhibitors and&#xD;
           identify new pathways of potential interests by performing gene expression profiling of&#xD;
           tumor tissues before and after exposure to celecoxib.&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized, uncontrolled study.&#xD;
&#xD;
      Patients undergo panendoscopy and tumor biopsy on day 0. Patients receive oral celecoxib&#xD;
      twice daily beginning on day 1 and continuing for at least 14 days*. Patients then undergo&#xD;
      definitive surgery.&#xD;
&#xD;
      NOTE: *Treatment continues until the day before surgery.&#xD;
&#xD;
      Tumor, blood, and urine samples are collected at baseline and periodically during study.&#xD;
      Tumor quantification by perfusion CT scan is performed at baseline and after treatment with&#xD;
      celecoxib. Biological markers are detected by immunohistochemistry and enzyme immunoassay.&#xD;
      Blood vascular density, apoptosis, proliferation, and endothelial cell:tumor ratio are&#xD;
      measured by indirect hemagglutination. Gene expression is measured by microarray analysis.&#xD;
&#xD;
      After surgery, patients are followed at 4 weeks and then periodically thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular markers of angiogenesis in tumor tissues (PGE2, VEGF, MMP-9, sFlt-1, ERK phosphorylation, PKB phosphorylation, and ErbB2 levels)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular markers in plasma (VEGF, MMP-9, and sFlt1)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular marker in urine (PGE2)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptosis/proliferation in tumor cells and endothelial cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression profiling in fresh tumor tissues (Erb-B2, c-IAP-2, PAI-1, MAPK-4, integrin α V, N-CAM, caspase 6, ErbB2 transducer, angiopoietin like-2, interleukin-8, and MMP13)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor perfusion imaging by perfusion CT scan</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed or high clinical suspicion of squamous cell carcinoma of the&#xD;
             oral cavity, oropharynx, hypopharynx, or larynx&#xD;
&#xD;
               -  No carcinoma of sinonasal or nasopharynx&#xD;
&#xD;
          -  Clinical stage T1-4, N0-2, M0 disease&#xD;
&#xD;
               -  Tumor must be considered resectable with planned surgical excision&#xD;
&#xD;
               -  No lymph nodes &gt; 6 cm (N3)&#xD;
&#xD;
               -  No distant metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  History of prior malignancy allowed if there is no evidence of recurrence or&#xD;
             metastases at the time of screening&#xD;
&#xD;
          -  No comorbidity that precludes operability&#xD;
&#xD;
          -  No known liver impairment&#xD;
&#xD;
          -  Known recent gastric or duodenal ulcer allowed if treated for &gt; 6 weeks prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  No known hypersensitivity to celecoxib&#xD;
&#xD;
          -  No known allergic reactions to sulfonamides, aspirin, or other NSAIDs&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             interfere with study compliance and follow-up schedule&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 2 months since prior and no other concurrent anticancer or investigational&#xD;
             drugs&#xD;
&#xD;
          -  More than 2 weeks since prior and no other concurrent nonsteroidal anti-inflammatory&#xD;
             drugs (NSAIDs) or corticosteroids&#xD;
&#xD;
          -  No prior radiotherapy to the head and neck region&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation&#xD;
&#xD;
          -  No concurrent administration of any of the following:&#xD;
&#xD;
               -  Other cyclooxygenase-2 inhibitors&#xD;
&#xD;
               -  Aspirin&#xD;
&#xD;
                    -  Low-dose aspirin for cardiovascular prophylaxis allowed&#xD;
&#xD;
               -  Aluminum and magnesium-containing antacids&#xD;
&#xD;
               -  ACE inhibitors&#xD;
&#xD;
               -  Furosemide&#xD;
&#xD;
               -  Known inhibitors of P450 2C9 (e.g., fluconazole, fluoxetine, fluvoxamin,&#xD;
                  isoniazid, omeprazole)&#xD;
&#xD;
               -  Known inducers of P450 2C9 (e.g., rifampin)&#xD;
&#xD;
               -  Lithium&#xD;
&#xD;
               -  Acenocoumarol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Luthi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>July 26, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <last_update_submitted>December 23, 2010</last_update_submitted>
  <last_update_submitted_qc>December 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2010</last_update_posted>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

